trans-Aconitic acid

Synonyms: 反式乌头酸
trans-Aconitic acid 是一种具有口服活性的乌头酸酶抑制剂,可非竞争性抑制柠檬酸向顺乌头酸的转化并竞争性抑制顺乌头酸向异柠檬酸的转化,还可在体外抑制 Leishmania donovani 前鞭毛体的生长、Leishmania donovani 无鞭毛体向前鞭毛体的转化以及巨噬细胞内 Leishmania donovani 无鞭毛体的体外增殖,因此可用于内脏利什曼病 (黑热病) 的相关研究。
产品编号: MS-J07473 纯度: 99.74% CAS No.: 4023-65-8 分子式: C6H6O6 分子量: 174.11
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in Water
询价
3-5 天
100mg
询价
3-5 天
500mg
询价
3-5 天
1g
询价
询价
5g
询价
询价

产品描述

trans-Aconitic acid 是一种具有口服活性的乌头酸酶抑制剂,可非竞争性抑制柠檬酸向顺乌头酸的转化并竞争性抑制顺乌头酸向异柠檬酸的转化,还可在体外抑制 Leishmania donovani 前鞭毛体的生长、Leishmania donovani 无鞭毛体向前鞭毛体的转化以及巨噬细胞内 Leishmania donovani 无鞭毛体的体外增殖,因此可用于内脏利什曼病 (黑热病) 的相关研究。

生物实验数据

生物活性 trans-Aconitic acid is an orally active aconitase inhibitor that non-competitively inhibits the conversion of citric acid to cis-aconitic acid and competitively inhibits the conversion of cis-aconitic acid to isocitric acid, and it also inhibits the in vitro growth of Leishmania donovani promastigotes, the conversion of Leishmania donovani amastigotes to promastigotes, and the in vitro proliferation of Leishmania donovani amastigotes within macrophages, and can therefore be used in research related to visceral leishmaniasis (kala-azar).
IC50 & Target ATP citrate synthase:>1 mM(Ki,rat)
体外研究
(In Vitro)

trans-Aconitic acid (10-20 mM; duration of culture) 可在 Ray 液体培养基中以 10 mM 和 20 mM 浓度抑制 Leishmania donovani (株系 MHOH/IN/88/DD8) 前鞭毛体的生长。
trans-Aconitic acid (2-20 mM; 24-96 h) 可强效抑制 Leishmania donovani (菌株 MHOH/IN/88/DD8) 无鞭毛体在体外向前鞭毛体的转化;在 96 h 内,2-10 mM 浓度下的抑制率为 60%-99%,20 mM 浓度下可实现完全抑制。
trans-Aconitic acid (2-10 mM; 4 days) 可抑制 Leishmania donovani (菌株 MHOH/IN/88/DD8) 无鞭毛体在 BALB/c 小鼠腹腔巨噬细胞中的体外增殖;在 2-10 mM 浓度下作用 4 天,其抑制率可达 60%-83%,并以浓度依赖的方式降低受感染巨噬细胞的比例。
trans-Aconitic acid (5-10 mM; 48-72 h) 于 5 mM 和 10 mM 浓度下,在孵育 48 h 或 72 h 后对 BALB/c 小鼠腹腔巨噬细胞的活力无显著影响。
trans-Aconitic acid (5-20 mM; up to 168 h) 可呈剂量依赖性地抑制体外培养的 L. donovani 前鞭毛体生长,且等摩尔的顺乌头酸或柠檬酸可逆转该抑制作用。
trans-Aconitic acid (2-10 mM; up to 120 h) 可在体外抑制 L. donovani 无鞭毛体向前鞭毛体的转化,其中 2 mM 浓度下抑制率达 95.2%,10 mM 浓度下可实现完全抑制。
trans-Aconitic acid (5-10 mM; 5 days) 可在体外抑制 BALB/c 小鼠腹腔巨噬细胞内 L. donovani 无鞭毛体的增殖;其中 5 mM 浓度可使每个巨噬细胞内的无鞭毛体数量减少 59.5%,10 mM 浓度的减少率则为 85.1%。

Cell Proliferation Assay

Cell Line: Leishmania donovani (strain MHOH/IN/88/DD8) promastigote
Concentration: 10 mM, 20 mM
Incubation Time: duration of culture
Result: Inhibited the growth of Leishmania donovani promastigotes in FCS-supplemented RPMI 1640 medium.\nInhibited the growth of Leishmania donovani promastigotes in Ray’s liquid medium.

Cell Differentiation Assay

Cell Line: Leishmania donovani (strain MHOH/IN/88/DD8) amastigote
Concentration: 2 mM, 5 mM, 10 mM, 20 mM
Incubation Time: 24 h, 48 h, 72 h, 96 h
Result: Reduced amastigote-to-promastigote transformation by 50% at 2 mM, 48 h; 55% at 2 mM, 72 h; 67% at 2 mM, 96 h.
Reduced amastigote-to-promastigote transformation by 69% at 5 mM, 48 h; 67% at 5 mM, 72 h; 82% at 5 mM, 96 h.
Achieved complete inhibition of amastigote-to-promastigote transformation through 72 h at 10 mM; reduced transformation by 99% at 10 mM, 96 h.
Achieved complete inhibition of amastigote-to-promastigote transformation through 96 h at 20 mM.

Cell Proliferation Assay

Cell Line: Leishmania donovani (strain MHOH/IN/88/DD8) amastigote (in BALB/c mouse peritoneal macrophages)
Concentration: 2 mM, 5 mM, 10 mM
Incubation Time: 4 days
Result: Inhibited amastigote multiplication by 60% at 2 mM, with 83% of macrophages remaining infected.
Inhibited amastigote multiplication by 74% at 5 mM, with 69% of macrophages remaining infected.
Inhibited amastigote multiplication by 83% at 10 mM, with 56% of macrophages remaining infected.

Cell Proliferation Assay

Cell Line: Leishmania donovani promastigotes
Concentration: 5 mM, 10 mM, 20 mM
Incubation Time: up to 168 h
Result: Inhibited multiplication of L.
donovani promastigotes in a dose-dependent manner.
Reversed its inhibitory effect after addition of an equimolar amount of cis-aconitic acid or citrate.

Cell Differentiation Assay

Cell Line: Leishmania donovani amastigotes
Concentration: 2 mM, 5 mM, 10 mM
Incubation Time: up to 120 h
Result: Inhibited transformation by 95.2% at 2 mM.
Completely inhibited transformation at 10 mM.
Showed slight transformation positivity after 96 h at 5 mM.

Cell Proliferation Assay

Cell Line: Leishmania donovani amastigotes (within BALB/c mouse peritoneal macrophages)
Concentration: 5 mM, 10 mM
Incubation Time: 5 days
Result: Reduced amastigotes per infected macrophage by 59.5% and reduced the percentage of infected macrophages by 25% at 5 mM.
Reduced amastigotes per infected macrophage by 85.1% and reduced the percentage of infected macrophages by 41.7% at 10 mM.
体内研究
(In Vivo)

trans-Aconitic acid (每日腹腔注射,连续 15 天,剂量为 200-400 mg/kg/天) 可使感染 L. donovani 的仓鼠肝脏寄生虫载量降低:200 mg/kg/天剂量下降低 70%,400 mg/kg/天剂量下降低 99%。
trans-Aconitic acid (最高 2000 mg/kg;腹腔注射) 对 BALB/c 小鼠无急性致死作用,腹腔给药剂量最高可达 2000 mg/kg。
trans-Aconitic acid (200-400 mg/kg/天;灌胃;腹腔注射;肌肉注射;每日给药;连续 20 天) 可剂量依赖性地抑制已建立内脏利什曼病的仓鼠的脾脏寄生虫载量,其中以 400 mg/kg/天的剂量经肌肉注射给药时抑制率高达 99.6%,并可将感染相关的器官重量增加水平降至接近正常水平。
trans-Aconitic acid (灌胃;每日给药;连续 5 天,剂量 200-400 mg/kg/day) 可呈剂量依赖性地降低感染 8 天急性内脏利什曼病的仓鼠的脾脏寄生虫载量,当以 400 mg/kg/day 剂量经口服给药时,抑制率可达 98.5%。
trans-Aconitic acid (灌胃;每日给药;连续 20 天;200-400 mg/kg/day) 可剂量依赖性地抑制感染内脏利什曼病 30 天的仓鼠的脾脏寄生虫载量,其中以 400 mg/kg/day 经口给药时抑制率达 99.8%。
Trans-aconitic acid (2.5-10 mM;水培暴露;培养第 10、12、14 天共处理 3 次) 以剂量和时间依赖的方式抑制 Glycine max 的生长与光合作用,其中 10 mM 处理的抑制作用最显著,包括使根鲜重降低 64%、Φₚₛᵢᵢ降低 56%、营养液吸收量降低 77%。

Animal Model: Syrian golden hamsters (male, 80-83 g body weight, intracardial infection with Leishmania donovani)
Dosage: 200 mg/kg/day; 400 mg/kg/day
Administration: i.p.; daily; 15 days
Result: Reduced total liver amastigote burden by 70% at 200 mg/kg/day.
Reduced spleen weight to 132 mg at 200 mg/kg/day.
Reduced liver weight to 2.35 g at 200 mg/kg/day.
Reduced total liver amastigote burden by 99% at 400 mg/kg/day.
Reduced spleen weight to 147 mg at 400 mg/kg/day.
Reduced liver weight to 2.28 g at 400 mg/kg/day.
Caused no adverse effect on body weight relative to controls.
Animal Model: Syrian golden hamsters (male; intracardial infection with Leishmania donovani promastigotes, established infection model)
Dosage: 200 mg/kg/day; 400 mg/kg/day
Administration: p.o.; i.p.; i.m.; daily; 20 consecutive days
Result: Suppressed spleen parasite burden by 73.2% and reduced elevated liver and spleen weights to near uninfected control values.
Suppressed spleen parasite burden by 98.2% and reduced liver and spleen weights to near uninfected control values.
Suppressed spleen parasite burden by 71.9% and reduced elevated liver and spleen weights to near uninfected control values.
Suppressed spleen parasite burden by 98.7% and reduced liver and spleen weights to near uninfected control values.
Suppressed spleen parasite burden by 77.0% and reduced elevated liver and spleen weights to near uninfected control values.
Suppressed spleen parasite burden by 99.6% and reduced liver and spleen weights to near uninfected control values.
性状 固体
颜色 White to off-white

化学信息

分子量 174.11
分子式 C6H6O6
CAS No. 4023-65-8
别名 反式乌头酸

储存&溶解度

体内实验配方
10% DMSO+90% Saline: 10 mg/mL (57.44 mM), Solution.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

H2O 中的溶解度 : 100 mg/mL (574.35 mM; 超声助溶)

可选溶剂浓度1 mg5 mg10 mg25 mg
H2O1 mM5.7435 mL28.7175 mL57.4350 mL143.5874 mL
5 mM1.1487 mL5.7435 mL11.4870 mL28.7175 mL
10 mM0.5743 mL2.8717 mL5.7435 mL14.3587 mL
15 mM0.3829 mL1.9145 mL3.8290 mL9.5725 mL
20 mM0.2872 mL1.4359 mL2.8717 mL7.1794 mL
25 mM0.2297 mL1.1487 mL2.2974 mL5.7435 mL
30 mM0.1914 mL0.9572 mL1.9145 mL4.7862 mL
40 mM0.1436 mL0.7179 mL1.4359 mL3.5897 mL
50 mM0.1149 mL0.5743 mL1.1487 mL2.8717 mL
60 mM0.0957 mL0.4786 mL0.9572 mL2.3931 mL
80 mM0.0718 mL0.3590 mL0.7179 mL1.7948 mL
100 mM0.0574 mL0.2872 mL0.5743 mL1.4359 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础